Immunoassay Interference Blocker Market size may increase substantially during the forecast timeframe of 2023-2032. The prevalence of chronic diseases is increasing across the world, with the expanding geriatric population serving as a major progression factor. According to the U.S. Census Bureau, the total population of adults aged 65 years and above is estimated to surpass 73.1 million by 2030. This will bolster the need for therapies such as immunoassay interference blockers to accurately diagnose and treat life-threatening illnesses.
The total expenditure on healthcare and research & development programs has also risen at a significant rate in recent years. For instance, in March 2022, the U.K. government committed funds worth USD 240 million to support the NHS in its health research into diagnostics and treatment. Such investments are likely to improve the adoption of immunoassay interference blocker market. Researchers are escalating their efforts to improve their clinical accuracy and enhance the quality of diagnosis of several diseases. Furthermore, governments are showing their support for the demand of the healthcare sector by launching initiatives to improve the quality of its medical infrastructure.
For example, in November 2022, the U.S. Centers for Disease Control and Prevention (CDC) awarded funds worth USD 3.2 billion to help local, state, and territorial governments across the country fortify their public health infrastructure and workforce. Such financial aid will help pharma companies in making innovative diagnostic solutions including immunoassay interference blockers to prevent faulty diagnostic interpretations, and consequently, strengthen the market outlook.
Based on product, global immunoassay interference blocker market is divided into detection interferences, antibody interferences, and surface interferences. The industry revenue from the antibody interference blocker segment is anticipated to register a commendable increase by 2032. These blockers are mainly used to decrease non-specific binding and other interferences, that specifically arise from anti-mouse antibodies, rheumatoid factor, and heterophilic antibodies, which can lead to false-positive results in both paired and competitive monoclonal sandwich assays and safeguard an assay's accuracy. Such factors are set to accelerate industry progress over the forthcoming years.
In terms of application, the immunoassay interference blocker industry is segmented into sandwich antigen detection, competitive ELISA, serological ELISA assays, and others. The competitive ELISA application segment is predicted to capture a sizeable share of the market by 2032. This method uses crude or impure samples and can selectively bind any antigen that may be present in the sample. Moreover, this technique offers high sensibility, specificity, and flexibility and is best suited for complex samples as they do not need to be purified before measurement.
Based on end use, the immunoassay interference blocker market size from the biotech & pharma company segment is predicted to record a notable CAGR during the forecast timeframe. The customer base of these organizations is expanding as there is a growing demand for advanced diagnostic and immunoassay solutions. These kits are also gaining momentum in the food sector as food safety standards have become increasingly stringent in recent years.
Several key diagnostic kit manufacturing firms are intensifying their research and development activities to offer improved diagnostic products that deliver the highest precision. For example, in September 2022, U.S.-based Neogen released its Veratox VIP for Cashew allergen test to identify cashew allergens, as part of its enhanced quantitative ELISA series under the Veratox VIP brand. Such launches are anticipated to enhance food safety, as well as augment industry development over the forecast period.
Europe immunoassay interference blocker market is projected to experience substantial progress during the analysis timeline. Major pharmaceutical companies in the region are raising their R&D investments to improve the quality of their diagnosis and treatment. Governments are also introducing favorable norms and programs to promote the manufacturing of these diagnostic kits. For example, the European Commission launched the ‘EU4Health program’ with a budget of USD 5.64 billion to support the healthcare sector. Such programs are expected to drive the development of novel immunoassay interference blockers and in turn, strengthen the regional market development .
Some of the notable players operating in the immunoassay interference blocker market include Roche Diagnostics, AMS Biotechnology, Aviva Systems Biology, Bio-Rad Laboratories, Abcam, Scantibodies Laboratory, Thermo Fisher Scientific, and Meridian Bioscience, among others.